* without additional immunocompromising conditions, by receipt of bivalent mRNA COVID-19 vaccine — United States, September 2022–March 2023" width="100%" height="100%">
Journal: Morbidity and Mortality Weekly Report
Article Title: Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023
doi: 10.15585/mmwr.mm7301a4
Figure Lengend Snippet: Characteristics of immunocompetent Medicare fee-for-service beneficiaries aged ≥65 years and beneficiaries aged ≥18 years with end stage renal disease receiving dialysis * without additional immunocompromising conditions, by receipt of bivalent mRNA COVID-19 vaccine — United States, September 2022–March 2023
Article Snippet: The signal was detected in a vaccinated concurrent comparator analysis and raised a question about whether receipt of a Pfizer-BioNTech bivalent COVID-19 mRNA vaccine increased the risk for an ischemic stroke event in the 21 days following vaccination in persons aged ≥65 years.
Techniques: Infection